Media Coverage

AgriLabs gets US patent for adjuvant tech

May 11, 2017 - Animal Pharm

By Joseph Harvey
Animal Pharm
May 11, 2017

US firm AgriLabs has received a patent covering the use of its ENABL adjuvant technology as a delivery system for the DNA vaccines the firm is developing.

The patent covers a broad range of adjuvant compositions and methods for human and animal health, said the St Joseph, Missouri-based company.

Steve Schram, president and chief executive of AgriLabs, said: "This is a major step in commercialization of our DNA vaccine platform for a number of animal species. DNA vaccines offer tremendous promise in terms of efficacy, safety and convenience, and ENABL technology is unique in its ability to help realize that potential."

AgriLabs is close to commercializing the first DNA vaccine platform in the US.

The ENABL adjuvant technology provides more efficient delivery of DNA-based vaccines, "which result in a higher absorption of antigen and greater immune response".

Dr Tim Miller, chief scientific officer at AgriLabs, commented: "ENABL adjuvants feature a lipid/polymer matrix that allows for more efficient delivery of both DNA and traditional vaccines to target cells. This means we have an expandable platform that can address issues such as reduced number of doses for DNA vaccines, which makes them economically viable options."

Another advantage of the DNA vaccines being developed by AgriLabs is their ease of transport and storgare, due to their stability in refrigeration and at room temperature.

Reprinted with permission of Animal Pharm News




News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum